A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL

Inclusion Criteria

• Age 18 through 60 years
• Written informed consent and any locally required authorization
• Body weight 45-150 kilogram (kg) for Cohorts 1-3, 4b, and 5-9. Body weight 45-90 kg for Cohort 4a
• Females must have been surgically sterilized or postmenopausal
• Non-sterilized males who are sexually active with a female partner of childbearing potential must use a highly effective method of contraception from Day 1 through Day 85; Both partners to use contraception
• Sterilized males must be at least 1-year post vasectomy or use a highly effective contraceptive method
• Healthy Japanese population as determined by a responsible physician
• Current diagnosis of allergic rhinitis, allergic asthma, or atopic dermatitis (cohorts 1-6) with a diagnostic immunoglobulin E (IgE) of 30 international units per milliliter (IU/mL) at Screening. Diagnostic IgE levels are further restricted for subjects enrolling into each cohort, with the following levels required at Screening: Cohorts 1 and 2: 30-700 IU/mL; Cohort 3: 30-700 IU/mL (4 subjects), greater than (>) 700-1,200 IU/mL (4 subjects), and >1,200 IU/mL (4 subjects); Cohort 4a: 30-500 IU/mL; Cohort 4b: >700 IU/mL; Cohorts 5 and 6: 30-700 IU/mL (4 subjects per cohort) and >700 IU/mL (6 subjects per cohort) or Japanese Cohorts 7-9: greater than or equal to (>=) 30 IU/mL
• Nonsmoker for >=6 months
• Obsolete criteria as no longer require Positive in vitro IgE fluorescence enzyme immunoassay (FEIA) response
• A forced expiration volume in one second (FEV1) >= 80 percent (%) predicted in subjects with asthma. Non-asthmatic subjects with FEV1 >=80% predicted, or with FEV1 less than ( = 1.5 times upper limit of normal (ULN)
• Unwillingness or inability to follow the procedures outlined in the protocol
• Positive test or history of hepatitis B or positive hepatitis C
• Positive test or history of human immunodeficiency virus (HIV) or subject is known to be HIV seropositive
• History of cancer, with the exception of basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success
• Women who are pregnant, breastfeeding, or lactating
• Plans to donate blood during the study period
• Hyper-IgE syndrome or bronchopulmonary aspergillosis
• Prior history of Immune Complex Disease or type 3 hypersensitivity reactions to MAb administration
• Known history of prior infusion reaction to MAb administration
• History of untreated parasitic/helminthic infection within 6 months prior to Screening
• Uses any of the following medications: a) Oral corticosteroids b) Medium to high dose Immunocorticosteroids (ICS)/ long-acting beta agonists (LABA) c) Immunosuppressives d) Beta blockers
• If receiving allergy immunotherapy, must be on stable dose for 3 months. Must not receive allergy immunotherapy within 7 days of investigational product administration.